First Light Asset Management Acquires 693,044 Shares in LENZ Therapeutics

Got story updates? Submit your updates here. ›

First Light Asset Management LLC acquired a new stake of 693,044 shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) during the third quarter, according to a recent SEC filing. The shares are valued at approximately $32.28 million, making LENZ Therapeutics the 10th largest holding in First Light Asset Management's investment portfolio.

Why it matters

The acquisition of a significant stake in LENZ Therapeutics by a major investment firm like First Light Asset Management signals confidence in the company's future prospects. As LENZ Therapeutics focuses on developing therapies to improve vision, this investment could provide the resources needed to advance its pipeline of drug candidates.

The details

According to the SEC filing, First Light Asset Management now owns 2.21% of LENZ Therapeutics' outstanding shares. The investment firm purchased the 693,044 shares during the third quarter of 2026. LENZ Therapeutics is a biopharmaceutical company headquartered in Del Mar, California that is developing treatments for presbyopia, a common age-related vision condition.

• First Light Asset Management acquired the 693,044 shares of LENZ Therapeutics during the third quarter of 2026.